Online inquiry

IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10768MR)

This product GTTS-WQ10768MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FGFR4 gene. The antibody can be applied in Non-alcoholic steatohepatitis (NASH) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001291980.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2264
UniProt ID P22455
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10768MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13251MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ5132MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CAN-04
GTTS-WQ9579MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ15831MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ4335MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BIW-8405
GTTS-WQ8467MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ2965MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ANB020
GTTS-WQ5957MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CL-2C
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW